28 – 29 October 2021 | London, UK
+ Digital Day: 01 November 2021 | Online

Annie Hubert

Senior Director, EU Section & Public Policy
Alliance for Regeneratice Medicine
Annie Hubert
Annie Hubert brings over 30 years of experience in European regulatory and government affairs, pricing, reimbursement and market access to the ARM Team. She came to ARM via the membership merger with the former Alliance for Advanced Therapies in the fall of 2014, where she had served as Director of Public Affairs since November 2013. In addition to her role at ARM, she is also Managing Director of ESAH (Expert Services and Advice in Healthcare), a consulting company founded in 2012, which provides services in healthcare biotech, with expertise in market access, regulatory and economic policy and government affairs relating to biopharmaceuticals and advanced therapies. In June 2012, Annie founded and is the director of Co-ACT, an association for small and medium-sized enterprises (SMEs) developing advanced therapies in Belgium. Between 2001 and 2011, Annie worked at Amgen as Corporate Affairs Director for their BeLux affiliate, and then as European Government and Public Affairs Director. Prior to Amgen, Annie worked as Regulatory Affairs Manager at Warner-Lambert (now Pfizer), Pharmacia (now Pfizer) and Beecham Research Laboratories (now GSK). She has been an active member in various industry associations and led a number of industry initiatives in the areas of Biotechnology and Health Technology Assessment. She periodically lectures on biotechnology topics in different educational courses for healthcare professionals and students in Belgium. Annie holds a Master in Pharmacy (UCL, Belgium) and has been qualified as an industrial pharmacist since 1983. She is a Belgian national and resides near Brussels.


No data was found